Ajanta Pharma has received final approval from the US Food and Drug Administration (FDA) to manufacture and market Zolmitriptan tablets, a drug used to treat migraine.
"This product is expected to be launched within two months from now," a company source said.
Zolmitriptan is a bioequivalent generic version of Zomig ® 1 and is a part of an ever-growing portfolio of products that Ajanta has developed for the US market.
USFDA has granted Ajanta Pharma 9 ANDA final approvals and two tentative approvals. Additional 15 ANDAs are under review with the FDA.
Ajanta Pharma is a specialty pharmaceutical formulation company with global headquarters in Mumbai. Over 6,000 employees are engaged in developing, manufacturing and marketing of quality finished dosages across 30 countries.
